Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 3Prostatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Carcinoma, Hepatocellular 1

Interventions

Doxorubicin 2tazemetostat 1romidepsin 1pembrolizumab 1etoposide phosphate 1duvelisib 1cc-486 1Vincristine 1Prednisone 1Prednisolone 1Melphalan 1Etoposide 1Cytarabine 1Cyclophosphamide 1Carmustine 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Enteropathy-Associated T-Cell Lymphoma × tazemetostat × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡